Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans

Pfizer’s 2024 revival tour is off and running, but the Big Pharma remains mum on one critical component of its future: treating obesity.

The New York-based drug developer declined to lay out a renewed vision for its metabolic pipeline during its investor call Wednesday, despite investors' clamoring for details. The questions about what’s next followed a dismal year for Pfizer’s initial bets, namely the discontinuation of lotiglipron and the reevaluation of twice-daily danuglipron.